RosaAnna DeFilippis on Muck Rack

RosaAnna DeFilippis

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with RosaAnna

Contact RosaAnna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML

|
By RosaAnna DeFilippis, Amal Kamal Abdel-Aziz, Nada Alaa El-Deen, Sandra N. Milik
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description ardp70002-sup-0001-ArchPharm_SupplMat_InChI.doc89 KB ArchPharm SupplMat InChI. ardp70002-sup-0002-Supplementary_Information.docx24.9 MB Supplementary Information. ardp70002-sup-0003-1_Apo-WT2.mp4424.3 KB 1_Apo-WT2. ardp70002-sup-0004-2_Apo-Mut2.mp4327.5 KB 2_Apo-Mut2. ardp70002-sup-0005-3_4ACP-WT2.mp4469.8 KB 3_4ACP-WT2. ardp70002-sup-0006-4_4ACP-Mut2.mp4419.5 KB 4_4ACP-Mut2.
Open in Who Shared Issue with article?

Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib - Leukemia

|
By Ian R. Outhwaite, Ji Young Lee, Aziz M. Rangwala, Markus A. Seeliger, RosaAnna DeFilippis
| Nature Verified
To the Editor: The recently approved BCR::ABL1 tyrosine kinase inhibitor (TKI) asciminib has demonstrated considerable activity and tolerability in newly diagnosed chronic phase chronic myeloid leukemia (CML) patients [1]. In contrast to previously approved BCR::ABL1 TKIs that target the ATP-binding (“orthosteric”) site, asciminib is a first-in-class allosteric TKI that targets the myristoyl-binding pocket in the C-lobe of ABL1 kinase (SRC homology-1; SH1).
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified